Aadi Bioscience (NASDAQ:AADI) Shares Climb 1.6% – Still a Buy?

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report)’s share price traded up 1.6% on Thursday. The company traded as high as $3.21 and last traded at $3.13. 284,344 shares traded hands during mid-day trading, an increase of 9% from the average session volume of 261,100 shares. The stock had previously closed at $3.08.

Aadi Bioscience Stock Performance

The firm’s 50 day moving average price is $3.45 and its 200-day moving average price is $3.84. The firm has a market capitalization of $77.30 million, a PE ratio of -1.37 and a beta of 0.68.

About Aadi Bioscience

(Get Free Report)

Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing therapies for cancers associated with specific genetic alterations. Its work has centered on precision medicines intended for patients with rare or difficult-to-treat tumors. The company’s lead product is FYARRO, an albumin-bound formulation of sirolimus. In the United States, FYARRO is approved for adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor, a rare cancer also known as malignant PEComa.

Further Reading

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.